Encision Reports Second Quarter Fiscal Year 2026 Results
Encision (PK:ECIA) reported fiscal Q2 2026 results for the quarter ended September 30, 2025: total net revenue $1.53M (product $1.48M; service $46K) and a net loss $0.27M or $(0.02) per diluted share.
Compared with the prior-year quarter, product revenue fell ~10%, total revenue fell ~13%, and gross profit was $697K. Cash was $71,731 at quarter end and the company recorded proceeds of $500K from issuance of common stock year-to-date. Encision expects a new ENT device launch in Q4 and continues R&D investment.
Encision (PK:ECIA) ha riportato i risultati del secondo trimestre fiscale 2026 per il trimestre terminato il 30 settembre 2025: entrate nette totali di $1.53M (prodotto $1.48M; servizio $46K) e una perdita netta di $0.27M o $(0.02) per azione diluita.
Rispetto al trimestre dell'anno precedente, le entrate da prodotto sono calate di circa il 10%, le entrate totali di circa il 13% e l'utile lordo è stato di $697K. La liquidità era di $71,731 al termine del trimestre e l'azienda ha registrato proventi di $500K dall'emissione di azioni ordinarie nel corso dell'anno. Encision prevede il lancio di un nuovo dispositivo ENT nel quarto trimestre e continua gli investimenti in ricerca e sviluppo.
Encision (PK:ECIA) reportó los resultados del segundo trimestre fiscal de 2026 para el trimestre terminado el 30 de septiembre de 2025: ingresos netos totales de $1.53M (producto $1.48M; servicio $46K) y una pérdida neta de $0.27M o $(0.02) por acción diluida.
En comparación con el trimestre del año anterior, los ingresos por producto cayeron aproximadamente un 10%, los ingresos totales cayeron alrededor de un 13% y la utilidad bruta fue de $697K. La liquidez fue de $71,731 al cierre del trimestre y la empresa registró ingresos de $500K por la emisión de acciones comunes en lo que va del año. Encision espera el lanzamiento de un nuevo dispositivo ENT en el cuarto trimestre y continúa invirtiendo en I+D.
Encision (PK:ECIA)가 2026 회계연도 2분기 실적을 2025년 9월 30일 종료된 분기에 대해 발표했습니다: 총 순매출 $1.53M (제품 $1.48M; 서비스 $46K) 및 순손실 $0.27M 또는 희석 주당 $(0.02)
전년 동분기 대비 제품 매출은 약 10%, 총매출은 약 13% 감소했고 매출총이익은 $697K였습니다. 현금 및 현금성자산은 분기말에 $71,731였고, 연초 이후 보통주 발행에서 $500K의 현금 유입이 기록되었습니다. Encision은 4분기에 새로운 ENT 기기 출시를 기대하며 연구개발에 대한 투자를 지속합니다.
Encision (PK:ECIA) a publié les résultats du deuxième trimestre fiscal 2026 pour le trimestre clos le 30 septembre 2025 : un chiffre d'affaires net total de 1,53 M$ (produit 1,48 M$; service 46 K$) et une perte nette de 0,27 M$ ou (0,02) $ par action diluée.
Par rapport au trimestre de l'exercice précédent, le revenu lié au produit a chuté d'environ 10 %, le revenu total d'environ 13 %, et la marge brute était de 697 K$. La trésorerie était de 71 731 $ à la fin du trimestre et l'entreprise a enregistré des produits de 500 K$ issus de l'émission d'actions ordinaires à ce jour. Encision prévoit le lancement d'un nouvel appareil ENT au quatrième trimestre et poursuit ses investissements en R&D.
Encision (PK:ECIA) berichtete die Ergebnisse des Geschäftsjahres-Q2 2026 für das Quartal zum 30. September 2025: Gesamtumsatz netto $1,53 Mio. (Produkt $1,48 Mio.; Service $46T) und ein Nettoverlust von $0,27 Mio. bzw. $(0,02) pro verwässerter Aktie.
Im Vergleich zum Vorjahresquartal sanken der Produktumsatz um ca. 10%, der Gesamtumsatz um ca. 13% und der Bruttogewinn betrug $697K. Die Cash-Position lag am Quartalsende bei $71.731, und das Unternehmen verzeichnete bis heute Zuflüsse von $500K aus der Emission von Stammaktien. Encision erwartet im vierten Quartal die Einführung eines neuen ENT-Geräts und setzt die F&E-Investitionen fort.
Encision (PK:ECIA) أبلغت عن نتائج الربع الثاني من السنة المالية 2026 للربع المنتهي في 30 سبتمبر 2025: إجمالي الإيرادات الصافية 1.53 مليون دولار (المنتج 1.48 مليون دولار؛ الخدمة 46 ألف دولار) وخسارة صافية قدرها 0.27 مليون دولار أو (0.02) دولار للسهم المخفف.
مقارنةً بالربع نفسه من العام الماضي، انخفضت إيرادات المنتج بنحو 10%، وانخفضت الإيرادات الإجمالية بنحو 13%، وكانت الهامش الإجمالي 697 ألف دولار. كانت السيولة النقدية 71,731 دولار في نهاية الربع وسجلت الشركة عوائد قدرها 500 ألف دولار من إصدار الأسهم العادية حتى تاريخه. تتوقع Encision إطلاق جهاز ENT جديد في الربع الرابع وتستمر في الاستثمار في البحث والتطوير.
- New ENT device expected to launch in Q4 2026
- R&D spending increased ~29.5% (YTD) indicating product investment
- Proceeds of $500,000 from issuance of common stock
- Total net revenue down ~12.9% year-over-year for the quarter
- Product net revenue down ~10.4% year-over-year for the quarter
- Quarterly net loss widened to $267,833 from $170,262 year-ago
- Cash balance fell to $71,731 from $257,433 at March 31, 2025
- Shares outstanding increased by ~42% (16.88M vs 11.88M), dilutive
BOULDER, CO / ACCESS Newswire / November 14, 2025 / Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2026 second quarter that ended September 30, 2025.
The Company posted quarterly product net revenue of
"Encision continues to fight the attrition of laparoscopic surgical procedure migration to robotics and is focusing our time and resources innovating in segments where robotics are not a factor," says Gregory Trudel the President and CEO of Encision. Our development efforts are culminating in the completion of a new device for the Ear Nose and Throat space that will deliver new levels of patient safety, surgical performance and efficiency, and significant cost savings to hospitals and surgery centers. We expect the product launch in our Q4 and are assembling sales channels and other necessary resources."
Encision Inc. designs and markets a portfolio of high-performance surgical instruments that deliver advances in patient safety, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring (AEM) technology to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2025, and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Brandon Shepard, Encision Inc., 303-444-2600, bshepard@encision.com
Encision Inc.
Condensed Balance Sheets
September 30, | March 31, | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 71,731 | $ | 257,433 | ||||
Accounts receivable | 761,947 | 786,471 | ||||||
Inventories | 1,468,863 | 1,483,182 | ||||||
Prepaid expenses | 144,331 | 85,679 | ||||||
Total current assets | 2,446,872 | 2,612,765 | ||||||
Equipment: | ||||||||
Furniture, fixtures and equipment, at cost | 2,628,661 | 2,585,446 | ||||||
Accumulated depreciation | (2,378,645 | ) | (2,340,689 | ) | ||||
Equipment, net | 250,016 | 244,757 | ||||||
Right of use asset | 1,116,454 | 568,395 | ||||||
Patents, net | 161,427 | 171,890 | ||||||
Other assets | 81,990 | 72,892 | ||||||
TOTAL ASSETS | $ | 4,056,759 | $ | 3,670,699 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 314,815 | $ | 346,900 | ||||
Line of credit | 31,706 | 395,964 | ||||||
Secured notes | 35,202 | 44,128 | ||||||
Accrued compensation | 199,657 | 180,850 | ||||||
Deferred Revenue | - | 17,401 | ||||||
Other accrued liabilities | 147,019 | 160,274 | ||||||
Accrued lease liability | 343,172 | 430,398 | ||||||
Total current liabilities | 1,071,571 | 1,575,915 | ||||||
Long-term liabilities: | ||||||||
Secured notes | 162,249 | 177,470 | ||||||
Accrued lease liability | 958,152 | 266,212 | ||||||
Total liabilities | 2,191,972 | 2,019,597 | ||||||
Commitments and contingencies (Note 4) | ||||||||
Shareholders' equity: | ||||||||
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding | - | - | ||||||
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 16,879,645 and 11,879,645 issued and outstanding at September 30, 2025, and March 31, 2025, respectively | 24,938,998 | 24,416,347 | ||||||
Accumulated (deficit) | (23,074,211 | ) | (22,765,245 | ) | ||||
Total shareholders' equity | 1,864,787 | 1,651,102 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 4,056,759 | $ | 3,670,699 | ||||
Encision Inc.
Condensed Statements of Operations
(Unaudited)
Three Months Ended | Six Months Ended | |||||||||||||||
September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||||||||||
NET REVENUE: | ||||||||||||||||
Product | $ | 1,481,802 | $ | 1,653,820 | $ | 2,974,634 | $ | 3,245,779 | ||||||||
Service | 46,248 | 101,568 | 156,144 | 140,539 | ||||||||||||
Total revenue | 1,528,050 | 1,755,388 | 3,130,778 | 3,386,318 | ||||||||||||
COST OF REVENUE: | ||||||||||||||||
Product | 805,734 | 882,886 | 1,472,545 | 1,550,520 | ||||||||||||
Service | 24,983 | 44,020 | 82,441 | 64,653 | ||||||||||||
Total cost of revenue | 830,717 | 926,906 | 1,554,986 | 1,615,173 | ||||||||||||
GROSS PROFIT | 697,333 | 828,482 | 1,575,792 | 1,771,145 | ||||||||||||
OPERATING EXPENSES: | ||||||||||||||||
Sales and marketing | 395,793 | 458,480 | 800,394 | 881,716 | ||||||||||||
General and administrative | 358,639 | 373,405 | 686,838 | 725,310 | ||||||||||||
Research and development | 201,392 | 155,515 | 366,832 | 294,695 | ||||||||||||
Total operating expenses | 955,824 | 987,400 | 1,854,064 | 1,901,721 | ||||||||||||
OPERATING (LOSS) | (258,491 | ) | (158,918 | ) | (278,272 | ) | (130,576 | ) | ||||||||
Interest expense, net | (11,384 | ) | (10,598 | ) | (29,393 | ) | (16,967 | ) | ||||||||
Other (expense) income, net | 2,042 | (746 | ) | (1,301 | ) | (679 | ) | |||||||||
Interest expense and other income (expense), net | (9,342 | ) | (11,344 | ) | (30,694 | ) | (17,646 | ) | ||||||||
(LOSS) BEFORE PROVISION FOR INCOME TAXES | (267,833 | ) | (170,262 | ) | (308,966 | ) | (148,222 | ) | ||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
NET (LOSS) | $ | (267,833 | ) | $ | (170,262 | ) | $ | (308,966 | ) | $ | (148,222 | ) | ||||
Net (loss) per share-basic and diluted | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.01 | ) | ||||
Weighted average shares-basic and diluted | 14,187,337 | 11,875,145 | 13,033,491 | 11,875,145 | ||||||||||||
Encision Inc.
Condensed Statements of Cash Flows
(Unaudited)
Six Months Ended | September 30, 2025 | September 30, 2024 | ||||||
Cash flows (used in) operating activities: | ||||||||
Net (loss) | $ | (308,966 | ) | $ | (148,222 | ) | ||
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||||||||
Depreciation and amortization | 48,570 | 42,525 | ||||||
Stock-based compensation expense related to stock options | 22,651 | 25,011 | ||||||
Provision for potential inventory obsolescence | 2,569 | 83,152 | ||||||
Change in operating assets and liabilities: | ||||||||
Right of use asset, net | 56,656 | (6,909 | ) | |||||
Accounts receivable | 24,524 | 74,127 | ||||||
Inventories | 11,750 | 154,520 | ||||||
Prepaid expenses and other assets | (55,968 | ) | 15,935 | |||||
Accounts payable | (49,487 | ) | (26,678 | ) | ||||
Accrued compensation and other accrued liabilities | 5,552 | (20,762 | ) | |||||
Net cash (used in) provided by operating activities | (242,149 | ) | 192,699 | |||||
Cash flows (used in) investing activities: | ||||||||
Acquisition of property and equipment | (43,215 | ) | (42,559 | ) | ||||
Patent and Trademark costs | (11,933 | ) | (17,359 | ) | ||||
Net cash (used in) investing activities | (55,148 | ) | (59,918 | ) | ||||
Cash flows from financing activities: | ||||||||
(Repayments) Borrowing from line of credit | (364,258 | ) | (77,834 | ) | ||||
(Payments) from options exercised | - | (1,449 | ) | |||||
Proceeds from issuance of common stock | 500,000 | - | ||||||
(Paydown) Draw on Secured notes | (24,147 | ) | 134,007 | |||||
Net cash provided by financing activities | 111,595 | 54,724 | ||||||
Net (decrease) increase in cash | (185,702 | ) | 187,505 | |||||
Cash, beginning of fiscal year | 257,433 | 42,509 | ||||||
Cash, end of six months | $ | 71,731 | $ | 230,014 | ||||
Supplemental disclosures of cash flow information: | ||||||||
Cash paid during the year for interest | $ | 29,393 | $ | 16,967 | ||||
SOURCE: Encision, Inc.
View the original press release on ACCESS Newswire
FAQ
What were Encision (ECIA) fiscal Q2 2026 total revenues on November 14, 2025?
How large was Encision's net loss for the quarter ended September 30, 2025 (ECIA)?
When does Encision (ECIA) expect to launch its new ENT device?
How much cash did Encision (ECIA) have at September 30, 2025?
Did Encision (ECIA) raise capital in fiscal 2026 year-to-date and how much?
How did Encision's product revenue change year-over-year in Q2 2026 (ECIA)?
